ANNX — Annexon, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1528115 ·
Last close
$5.09
Market Cap
$834.78M
52W High
$6.58
52W Low
$4.46
ADV30
4,624,610
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,053,000 | -44,142,000 | 262,888,000 | 175,208,000 | 58,355,000 |
| Dec 2025 | 0 | — | -50,258,000 | -48,256,000 | 277,571,000 | 162,051,000 | 65,923,000 |
| Sep 2025 | 0 | — | -57,018,000 | -54,922,000 | 229,142,000 | 139,419,000 | 67,700,000 |
| Jun 2025 | 0 | — | -51,726,000 | -49,156,000 | 264,573,000 | 132,288,000 | 65,556,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-186,356,000
Investing CF
$190,052,000
Financing CF
$108,855,000
CapEx
$-143,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.36
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-917,389,000
Inventory
—
Receivables
—
ST Investments
$76,294,000
EBIT TTM
$-216,407,000
Pretax Income TTM
$-206,690,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -216,407,000 | -206,690,000 | 277,571,000 | 65,923,000 | — | -186,356,000 |
| Dec 2024 | 0 | -154,073,000 | -138,200,000 | 350,071,000 | 56,966,000 | — | -118,006,000 |
| Dec 2023 | 0 | -143,723,000 | -134,237,000 | 297,674,000 | 47,118,000 | — | -121,142,000 |
| Dec 2022 | 0 | -145,599,000 | -141,947,000 | 285,096,000 | 53,902,000 | — | -116,309,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.99
Max Pain — expiry 2026-10-16
max pain strike: $6.00 · spot: $5.09 · call oi: 2,450 · put oi: 2,671
Expected Move to 2026-10-16:
±$2.25
(44.16%) —
implied range
$2.84 –
$7.34
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GERN | GERON CORP | $827.56M | $1.29 | — |
| IVEVF | Inventiva S.A. | $848.03M | $3.59 | — |
| OMER | OMEROS CORP | $856.92M | $11.84 | — |
| ABUS | Arbutus Biopharma Corp | $857.31M | $4.34 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $806.33M | $0.77 | — |
News headlines (Yahoo Finance, 1h cache)
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
2026-07-30 20:01 · Yahoo
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates
2026-07-16 23:17 · Yahoo
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-07-16 20:05 · Yahoo
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
2026-07-14 20:05 · Yahoo
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
2026-06-09 13:06 · Yahoo
Exploring 3 High Growth Tech Stocks in the US Market
2026-06-09 11:38 · Yahoo
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
2026-06-04 07:07 · Yahoo
Annexon to Participate in Upcoming June Investor Conferences
2026-05-27 12:00 · Yahoo
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
2026-05-14 08:05 · Yahoo
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
2026-05-11 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.